FBR Capital Remains Buyers of CVS Health (CVS) Following 'Solid' Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to FBR Capital Remains Buyers of CVS Health (CVS) Following 'Solid' Quarter
August 2, 2016 11:56 AM EDT
On Monday, CVS Health (NYSE: CVS) released its 2017 Standard Formulary Exclusion List and Express Scripts (NASDAQ: ESRX) released its 2017 National Preferred Formulary exclusion list.
Below is a summary of analyst commentary around the list changes:
CVS 2017 Standard Formulary Exclusion List:
Barclays analyst Eric Percher said most notably, CVS signaled aggressively on biosimilars, replacing Neupogen with Zarxio (limited impact under the pharmacy benefit) and Lantus with Basaglar for 2017 (significant impact under the pharmacy benefit)
Percher noted a therapeutics focus on Oncology,... More
August 2, 2016 9:29 AM EDT
CVS Health (NYSE: CVS) to Exclude Sanofi's (NYSE: SNY) Lantus in 2017 from Main Covered Drug List - Bloomberg
...
More
August 2, 2016 9:10 AM EDT
CVS Health (NYSE: CVS) to Exclude Medivation's (Nasdaq: MDVN) Xtandi in 2017 Main Formulary - Bloomberg
...
More
August 2, 2016 6:56 AM EDT
CVS Health (NYSE: CVS) reported Q2 EPS of $1.32, $0.02 better than the analyst estimate of $1.30. Revenue for the quarter came in at $43.7 billion versus the consensus estimate of $44.28 billion.
Same store sales increased 2.1% versus the second quarter of 2015. Pharmacy same store sales rose 3.9% and... More
